Promising investigational therapeutic monoclonal antibody to treat chronic hepatitis B and D infections

Affecting hundreds of millions of people, chronic hepatitis B is a widespread global health problem for which there is as yet no cure. In a preclinical study involving the German Center for Infection Research (DZIF), Heidelberg University Hospital, University Medical Center Hamburg-Eppendorf and the US company Vir Biotechnology, the potential of an engineered investigational human monoclonal antibody for the treatment of chronic hepatitis B and hepatitis D has been demonstrated. Based on the results, clinical trials with the monoclonal antibody VIR-3434 are ongoing.

GOV’T CHALLENGED TO UPDATE NATION ON UTILISATION OF US$300M

By PRINCE MABUMBA

CHILUBI Member of Parliament Mulenga Fube has challenged the Ministry of Agriculture to tell the nation on how the US$300 million allocated to farming bloks has been utilised since the time it was disbursed.

This content is locked

This is exclusive material. To read full story, click on register and choose one of the premium subscriptions to view this content. Login if you are already a premium user.


Exploring what happens in the brain under the influence of psychedelics, while meditating and during hypnosis

Changes in a person’s “normal” mental state after taking drugs, while meditating, during hypnosis or due to specific medical conditions have been a topic of study for several years now. Some of these mental changes, which are known as altered states of consciousness, have been found to have potentially beneficial effects, reducing stress and fostering greater well-being.